The Team

Roland B. Stoughton, PhD – CEO, President, and Founder

Formerly an applied physicist, and most recently Sr. V.P. for Informatics at the Rosetta Inpharmatics division of Merck & Co., Stoughton brings scientific depth and over 25 years of engineering and management experience. Stoughton built the Rosetta informatics group from scratch and was instrumental in Rosetta’s IPO and later acquisition by Merck. Stoughton’s publications span the fields of astrophysics, geophysics, acoustics, signal processing, and biotechnology. Before entering biotechnology in the early 1990s, Stoughton held various R&D and technical management positions at Science Applications International Corporation, contributing to critical national defense programs. Since then he has been a key member of three biotech startups each of which was financially successful, holds 16 issued biotechnology patents, and has contributed life sciences publications in several major journals.

Samuel "Scott" Beckey - Chief Operating Officer

Mr. Beckey was Vice President of Aurora Biosciences Corporation in 1996 – 2002, responsible for building the product development teams, architecting Aurora's drug discovery systems, delivering $70 million in deals with pharmaceutical companies, and defining merger and acquisition activities. Aurora reached a market capitalization of $2 B in 2001 and was acquired by Vertex Pharmaceuticals. Since 2002, Mr. Beckey has served as President and CEO of Xystus Corporation, and as Partner and VP Operations of Horn & Associates, a financial services company focused on federal, state, and municipal external auditing.

Daniel Shoemaker, PhD – Chief Scientific Officer

After receiving his PhD in Biochemistry at Stanford University, Dr. Shoemaker joined Rosetta Inpharmatics in 1998 where he initially led an R&D group to develop novel applications of the company’s proprietary ink-jet microarray technology. Dr. Shoemaker went on to lead a Genomic Discovery group at Rosetta that mined the draft human genome for novel drug targets and developed methods for monitoring alternative splicing on a genome-wide scale. Dr. Shoemaker’s expertise in integrating technology, informatics, and biology has allowed him to develop innovative approaches for addressing large-scale biological questions.

Mr. Michael Meyer – Director of Laboratories

At the Fred Hutchinson Cancer Research Center Mr. Meyer’s discovery and characterization of mutations in a key signaling protein led to improvements in the understanding of the orchestration of cytoskeletal rearrangements involved in cell morphogenesis and cell movements during embryogenesis. As one of the first scientists to join Rosetta Inpharmatics Mr. Meyer was a key contributor to development of its microarray platforms and methodology. At Rosetta Mr. Meyer also was responsible for evaluation and integration of new technologies and new methods to support the end-to-end processing of thousands of microarray experiments per month. During this period Mr. Meyer was co-author on several major Rosetta publications, including articles in Science, Cell, and Nature as well as a co-inventor on three patent applications related to microarray technology and nucleic acid detection.